Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of FOLFIRI-Induced Diarrhea in Patient with Metastatic Rectal Cancer Treated with Modified Wiryeong-tang

전이 직장암 환자의 FOLFIRI 유발 설사에 위령탕 가감방 치험 1례

  • Yoon, Sung Soo (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Kim, Eun Hye (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Lee, Jee Young (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Yoon, Seong Woo (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong)
  • 윤성수 (강동경희대학교병원 한방암센터 한방내과) ;
  • 김은혜 (강동경희대학교병원 한방암센터 한방내과) ;
  • 이지영 (강동경희대학교병원 한방암센터 한방내과) ;
  • 윤성우 (강동경희대학교병원 한방암센터 한방내과)
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : This study was aimed to describe a case of a patient with FOLFIRI-induced diarrhea, which was improved by treatment with Korean herbal medicine, modified Wiryeong-tang. Methods : The patient with metastatic rectal cancer recieved FOLFIRI plus bevacizumab as a palliative chemotherapy and showed repetitive diarrhea despite administration of loperamide, which was treated with modified Wiryeong-tang. To evaluate the effect of the treatment, the Bristol Stool Form Scale and bowel movement frequency were checked. Results : During the treatment, the stool form using Bristol Stool Form Scale was improved from diarrhea to normal stool, and the bowel movement frequency was decreased. Conclusions : The result suggest that modified Wiryeong-tang may be an effective treatment for FOLFIRI-induced diarrhea.

Keywords

References

  1. National Cancer Institute. Common Terminology Criteria for Adverse Events v5.0. p. 25, NCI, NIH, DHHS, 2017
  2. Rothenberg ML, Eckardt JR, Kuhn JG et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14(4):1128-1135, 1996 https://doi.org/10.1200/JCO.1996.14.4.1128
  3. Xu RH, Muro K, Morita S et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol 19(5):660-671, 2018 https://doi.org/10.1016/S1470-2045(18)30140-2
  4. Maroun JA, Anthony LB, Blais N et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol 14(1):13-20, 2007 https://doi.org/10.3747/co.2007.96
  5. 허준. 국역증보 동의보감. p. 191, 서울, 남산당, 1998
  6. Edge SB, Byrd D, Compton C et al. AJCC Cancer Staging Manual 7th Edition. p. 144, New York, Springer, 2010
  7. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32(9):920-924, 1997 https://doi.org/10.3109/00365529709011203
  8. Richardson G, Dobish R. Chemotherapy induced diarrhea. J Oncol Pharm Pract 3(4):181-198, 2007 https://doi.org/10.1200/JOP.0740501
  9. Benson AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918-2926, 2004 https://doi.org/10.1200/JCO.2004.04.132
  10. Muehlbauer PM, Thorpe D, Davis A et al. Putting evidence into practice: evidence-based interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clin J Oncol Nurs 13(3):336-341, 2009 https://doi.org/10.1188/09.CJON.336-341
  11. Wadler S, Benson AB, Engelking C et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol 16(9):3169-3178, 1998 https://doi.org/10.1200/JCO.1998.16.9.3169
  12. Upadhyay A, Bodar V, Malekzadegan M et al. Loperamide Induced Life Threatening Ventricular Arrhythmia. Case Rep Cardiol volume 2016, article ID 5040176, 2016 Available from:URL:http://dx.doi.org/10.1155/2016/5040176
  13. Marraffa JM, Holland MG, Sullivan RW et al. Cardiac conduction disturbance after loperamide abuse. Clin Toxicol (Phila) 52(9):952-957, 2014 https://doi.org/10.3109/15563650.2014.969371
  14. Mego M, Chovanec J, Vochyanova-Andrezalova I et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med 23(3):356-362, 2015 https://doi.org/10.1016/j.ctim.2015.03.008
  15. de Jong FA, Kehrer DF, Mathijssen RH et al. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11(8):944-954, 2006 https://doi.org/10.1634/theoncologist.11-8-944
  16. Michael M, Brittain M, Nagai J et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 22(21):4410-4417, 2004 https://doi.org/10.1200/JCO.2004.11.125
  17. Mori K, Kondo T, Kamiyama Y et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51(5):403-406, 2003 https://doi.org/10.1007/s00280-003-0585-0
  18. Kummar S, Copur MS, Rose M et al. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer 10(2):85-96, 2011 https://doi.org/10.1016/j.clcc.2011.03.003